143 related articles for article (PubMed ID: 28478358)
1. Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.
Young AH; Evitt L; Brignone M; Diamand F; Atsou K; Campbell R; Cure S; Danchenko N
J Affect Disord; 2017 Aug; 218():291-298. PubMed ID: 28478358
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
Soini E; Hallinen T; Brignone M; Campbell R; Diamand F; Cure S; Aalto-Setälä M; Danchenko N; Koponen H; Kolasa K
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):293-302. PubMed ID: 27680105
[TBL] [Abstract][Full Text] [Related]
3. The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence.
Lomas J; Llewellyn A; Soares M; Simmonds M; Wright K; Eastwood A; Palmer S
Pharmacoeconomics; 2016 Sep; 34(9):901-12. PubMed ID: 27289476
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
Choi SE; Brignone M; Cho SJ; Jeon HJ; Jung R; Campbell R; Francois C; Milea D
Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):629-638. PubMed ID: 26641142
[TBL] [Abstract][Full Text] [Related]
5. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.
Annemans L; Brignone M; Druais S; De Pauw A; Gauthier A; Demyttenaere K
Pharmacoeconomics; 2014 May; 32(5):479-93. PubMed ID: 24554474
[TBL] [Abstract][Full Text] [Related]
7. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Leelahanaj T
J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
[TBL] [Abstract][Full Text] [Related]
8. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
9. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.
Armstrong EP; Malone DC; Erder MH
Curr Med Res Opin; 2008 Apr; 24(4):1115-21. PubMed ID: 18331669
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.
Brignone M; Diamand F; Painchault C; Takyar S
Curr Med Res Opin; 2016; 32(2):351-66. PubMed ID: 26637048
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.
Maniadakis N; Kourlaba G; Mougiakos T; Chatzimanolis I; Jonsson L
BMC Health Serv Res; 2013 May; 13():173. PubMed ID: 23663281
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
Thase ME; Danchenko N; Brignone M; Florea I; Diamand F; Jacobsen PL; Vieta E
Eur Neuropsychopharmacol; 2017 Aug; 27(8):773-781. PubMed ID: 28663124
[TBL] [Abstract][Full Text] [Related]
13. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
Wade AG; Toumi I; Hemels ME
Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
[TBL] [Abstract][Full Text] [Related]
14. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Vieta E; Sluth LB; Olsen CK
J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
Nguyen KH; Gordon LG
Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G
J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
Atsou K; Ereshefsky L; Brignone M; Danchenko N; Diamand F; Mucha L; Touya M; Becker R; François C
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):29-42. PubMed ID: 33307885
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
Nordström G; Danchenko N; Despiegel N; Marteau F
Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
[TBL] [Abstract][Full Text] [Related]
19. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Li G; Wang X; Ma D
Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]